Targetable long non-coding RNAs in cancer treatments

Liang Chen; Emmanuel Enoch Dzakah; Ge Shan

doi:10.1016/j.canlet.2018.01.042

Targetable long non-coding RNAs in cancer treatments

Cancer Lett. 2018 Apr 1:418:119-124. doi: 10.1016/j.canlet.2018.01.042. Epub 2018 Jan 16.

Authors

Liang Chen¹, Emmanuel Enoch Dzakah², Ge Shan³

Affiliations

¹ CAS Key Laboratory of Innate Immunity and Chronic Disease, CAS Center for Excellence in Molecular Cell Science, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui Province 230027, China. Electronic address: anqingcl@ustc.edu.cn.
² CAS Key Laboratory of Innate Immunity and Chronic Disease, CAS Center for Excellence in Molecular Cell Science, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui Province 230027, China.
³ CAS Key Laboratory of Innate Immunity and Chronic Disease, CAS Center for Excellence in Molecular Cell Science, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui Province 230027, China. Electronic address: shange@ustc.edu.cn.

PMID: 29341880
DOI: 10.1016/j.canlet.2018.01.042

Abstract

Aberrant expression of many long non-coding RNAs has been observed in various types of cancer, implicating their crucial roles in tumorigenesis and cancer progression. Emerging knowledge with regard to the critical physiological and pathological roles of long non-coding RNAs in cancers makes them potential targets in cancer treatments. In this review, we present a summary of the relatively well studied long non-coding RNAs that are involved in oncogenesis and outline their functions and functional mechanisms. Recent findings that may be utilized in therapeutic intervention are also highlighted. With the fast development in nucleic acid-based therapeutic reagents that can target disease associated RNAs, lncRNAs should be explored as potential targets in cancer treatments.

Keywords: Cancer; Dysregulation; Oncogenesis; Therapeutics; lncRNA.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antineoplastic Agents / therapeutic use
Biomarkers, Tumor / antagonists & inhibitors
Biomarkers, Tumor / genetics*
Gene Expression Regulation, Neoplastic / drug effects
Gene Expression Regulation, Neoplastic / genetics*
Humans
Molecular Targeted Therapy / methods
Neoplasms / drug therapy
Neoplasms / genetics*
RNA, Long Noncoding / genetics*

Substances

Antineoplastic Agents
Biomarkers, Tumor
RNA, Long Noncoding